1. Home
  2. TFC vs ARGX Comparison

TFC vs ARGX Comparison

Compare TFC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Truist Financial Corporation

TFC

Truist Financial Corporation

HOLD

Current Price

$49.25

Market Cap

63.5B

Sector

Finance

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$750.26

Market Cap

52.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFC
ARGX
Founded
1872
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.5B
52.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TFC
ARGX
Price
$49.25
$750.26
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
$56.46
$991.56
AVG Volume (30 Days)
7.9M
339.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.55
$40.84
Revenue Next Year
$4.34
$22.38
P/E Ratio
$13.80
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$33.56
$510.06
52 Week High
$56.20
$934.62

Technical Indicators

Market Signals
Indicator
TFC
ARGX
Relative Strength Index (RSI) 41.20 29.84
Support Level $48.33 $698.92
Resistance Level $51.19 $779.00
Average True Range (ATR) 1.48 20.89
MACD -0.44 -10.01
Stochastic Oscillator 19.39 6.71

Price Performance

Historical Comparison
TFC
ARGX

About TFC Truist Financial Corporation

Truist Financial is one of the three super-regional banks in the US, with roughly $545 billion in assets as of the second quarter of 2025. Truist emerged from the combination of BB&T and SunTrust in 2019. Based in Charlotte, North Carolina, the bank's footprint is largely in the Mid-Atlantic and Southeast. Apart from retail and commercial banking operations, the bank also offers online and point-of-sale consumer lending, cards, wealth management, investment banking, and other banking services.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: